Lineage Cell Therapeutics (LCTX) Q4 2025 earnings summary

Executive summary

• Achieved key milestones in cell therapy programs, including OpRegen for dry AMD, OPC1 for spinal cord injury, and Resonance for hearing loss, with expanded clinical sites and new research initiatives in islet cell therapy for diabetes.

• Achieved first milestone under $620M collaboration with Genentech/Roche for OpRegen, reflecting manufacturing and clinical progress.

• Demonstrated manufacturing scalability with AlloSCOPE platform, enabling production of millions of cell doses and supporting commercial viability.

• Entered collaboration with William Demant Invest to fund preclinical development of Resonance (ANP1) for hearing loss.

• Secured significant funding through warrant exercises, milestone payments, and partnerships, extending operational runway into Q2 2028.

Financial highlights

• Q4 2025 revenues were $6.6 million, up $3.7 million year-over-year, driven by milestone and collaboration payments.

• Full year 2025 revenues were $14.6 million, up $5.1 million year-over-year.

• Full year 2025 net loss was $63.5 million, or $0.28 per share, compared to $18.6 million, or $0.09 per share, in 2024, mainly due to non-cash warrant liability remeasurement and impairment loss.

• Q4 2025 net income was $0.9 million, or $0.004 per share, compared to a net loss of $3.3 million, or $0.02 per share, in Q4 2024.

• Q4 operating expenses rose to $13.2 million, with R&D at $8.2 million and G&A at $4.8 million, both increasing year-over-year.

Outlook and guidance

• Operational runway extended into Q2 2028, not including potential future milestone payments or new partnerships.

• Focus remains on advancing OpRegen, scaling islet cell manufacturing, and expanding the pipeline with new cell types.

• Priorities for 2026 include achieving key clinical and financial milestones, advancing manufacturing, and expanding the pipeline.

• Additional cell type program expected to be announced within the next 3–6 weeks.